{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T06:27:00Z","timestamp":1759991220941},"reference-count":135,"publisher":"Baishideng Publishing Group Inc.","issue":"32","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["WJH"],"published-print":{"date-parts":[[2016]]},"DOI":"10.4254\/wjh.v8.i32.1343","type":"journal-article","created":{"date-parts":[[2016,11,16]],"date-time":"2016-11-16T23:04:40Z","timestamp":1479337480000},"page":"1343","source":"Crossref","is-referenced-by-count":14,"title":["Anti-hepatitis C virus drugs and kidney"],"prefix":"10.4254","volume":"8","author":[{"given":"Paul","family":"Carrier","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"Essig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marilyne","family":"Debette-Gratien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denis","family":"Sautereau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annick","family":"Rousseau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Marquet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00e9r\u00e9mie","family":"Jacques","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V\u00e9ronique","family":"Loustaud-Ratti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2060","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.2353\/ajpath.2006.050491"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2012.08.040"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2013.12.005"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12413"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2014-308163"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jis385"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2013-306102"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2013.02.010"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.5.1.95"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26602"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/liv.12631"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(15)30103-3"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/liv.13102"},{"key":"ref14","unstructured":"AFEF. Soci\u00e9t\u00e9 Fran\u00e7aise d\u1fbfH\u00e9patologie, Recommandations sur la prise en charge des h\u00e9patites virales C, f\u00e9vrier 2016. Available from: http:\/\/www.afef.asso.fr\/ckfinder\/userfiles\/files\/recommandations-textes-officiels\/Recommandations_AFEF_HepatiteC_Final-02-2016.pdf<\/ext-link>."},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.03.025"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27950"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00349-9"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2016.02.078"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1067\/mcp.2000.110973"},{"key":"ref20","unstructured":"European Medicines Agency. Résumé des caractéristiques du produit Pegasys. Available from: http:\/\/www.ema.europa.eu\/docs\/fr_FR\/document_library\/EPAR_-_Product_Information\/human\/000395\/WC500039195.pdf<\/ext-link>."},{"key":"ref21","unstructured":"European Medicines Agency. Résumé des caractéristiques du produit Pegintron. Available from: http:\/\/www.ema.europa.eu\/docs\/fr_FR\/document_library\/EPAR_-_Product_Information\/human\/000280\/WC500039388.pdf<\/ext-link>."},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Gad SC. Handbook of Pharmaceutical Biotechnology. John Wiley & Sons;. 2007;.","DOI":"10.1002\/0470117117"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199019050-00003"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1586\/eri.09.5"},{"key":"ref25","unstructured":"European Medicines Agency. Résumé des caractéristiques du produit Rebetol. Available from: http:\/\/www.ema.europa.eu\/docs\/fr_FR\/document_library\/EPAR_-_Product_Information\/human\/000246\/WC500048210.pdf<\/ext-link>."},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0138091"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000000516"},{"key":"ref28","unstructured":"European Medicines Agency. Résumé des caractéristiques du produit Incivo. Available from: http:\/\/www.ema.europa.eu\/docs\/fr_FR\/document_library\/EPAR_-_Product_Information\/human\/002313\/WC500115529.pdf<\/ext-link>."},{"key":"ref29","unstructured":"European Medicines Agency. Résumé des caractéristiques du produit Victrelis. Available from: http:\/\/www.ema.europa.eu\/docs\/fr_FR\/document_library\/EPAR_-_Product_Information\/human\/002332\/WC500109786.pdf<\/ext-link>."},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2012.07.032"},{"key":"ref31","unstructured":"European Medicines Agency. Résumé des caractéristiques du produit Sovaldi. Available from: http:\/\/www.ema.europa.eu\/docs\/fr_FR\/document_library\/EPAR_-_Product_Information\/human\/002798\/WC500160597.pdf<\/ext-link>."},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-015-0261-7"},{"key":"ref33","unstructured":"European Medicines Agency. Résumé des caractéristiques du produit Olysio. Available from: http:\/\/www.ema.europa.eu\/docs\/fr_FR\/document_library\/EPAR_-_Product_Information\/human\/002777\/WC500167867.pdf<\/ext-link>."},{"key":"ref34","unstructured":"European Medicines Agency. Résumé des caractéristiques du produit Daklinza. Available from: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/003768\/WC500172848.pdf<\/ext-link>."},{"key":"ref35","unstructured":"European Medicines Agency. Résumé des caractéristiques du produit Harvoni. Available from: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/003850\/WC500177995.pdf<\/ext-link>."},{"key":"ref36","unstructured":"Mogalian E. The Pharmacokinetics of Ledipasvir, an HCV Specific NS5A Inhibitor, in HCV-Uninfected Subjects with Severe Renal Impairment. Available from: http:\/\/liverlearning.aasld.org\/aasld\/2014\/thelivermeeting\/61996\/erik.mogalian.the.pharmacokinetics.of.ledipasvir.an.hcv.specific.ns5a.html?f=m3l1343<\/ext-link>."},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-015-0334-7"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(15)30915-6"},{"key":"ref39","unstructured":"Gutiérrez F, Fulladosa X, Barril G, Domingo P. Renal tubular transporter-mediated interactions of HIV drugs: implications for patient management. AIDS Rev 2014;16:199-212."},{"key":"ref40","unstructured":"European Medicines Agency. Résumé des caractéristiques du produit Exviera. Available from: http:\/\/www.ema.europa.eu\/docs\/fr_FR\/document_library\/EPAR_-_Product_Information\/human\/003837\/WC500182233.pdf<\/ext-link>."},{"key":"ref41","unstructured":"European Medicines Agency. Résumé des caractéristiques du produit Viekirax. Available from: http:\/\/www.ema.europa.eu\/docs\/fr_FR\/document_library\/EPAR_-_Product_Information\/human\/003839\/WC500183997.pdf<\/ext-link>."},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-016-0429-9"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1517\/17425255.2016.1148685"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27533"},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"Russo MW, Fried MW. Side effects of therapy for chronic hepatitis C. Gastroenterology 2003;124:1711-1719.","DOI":"10.1016\/S0016-5085(03)00394-9"},{"key":"ref46","doi-asserted-by":"crossref","unstructured":"Dimitrov Y, Heibel F, Marcellin L, Chantrel F, Moulin B, Hannedouche T. Acute renal failure and nephrotic syndrome with alpha interferon therapy. Nephrol Dial Transplant 1997;12:200-203.","DOI":"10.1093\/ndt\/12.1.200"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198811243192107"},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"Shah M, Jenis EH, Mookerjee BK, Schriber JR, Baer MR, Herzig GP, Wetzler M. Interferon-alpha-associated focal segmental glomerulosclerosis with massive proteinuria in patients with chronic myeloid leukemia following high dose chemotherapy. Cancer 1998;83:1938-1946.","DOI":"10.1002\/(SICI)1097-0142(19981101)83:9<1938::AID-CNCR9>3.0.CO;2-M"},{"key":"ref49","doi-asserted-by":"crossref","unstructured":"Ohta S, Yokoyama H, Wada T, Sakai N, Shimizu M, Kato T, Furuichi K, Segawa C, Hisada Y, Kobayashi K. Exacerbation of glomerulonephritis in subjects with chronic hepatitis C virus infection after interferon therapy. Am J Kidney Dis 1999;33:1040-1048.","DOI":"10.1016\/S0272-6386(99)70140-X"},{"key":"ref50","doi-asserted-by":"crossref","unstructured":"Al Harbi A, Al Ghamdi S, Subaity Y, Khalil A. Interferon-induced acute renal failure in nephrotic syndrome. Nephrol Dial Transplant 1998;13:1316-1318.","DOI":"10.1093\/ndt\/13.5.1316"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1007\/s11255-009-9594-1"},{"key":"ref52","doi-asserted-by":"crossref","unstructured":"Fisher ME, Rossini M, Simmons E, Harris RC, Moeckel G, Zent R. A woman with chronic hepatitis C infection and nephrotic syndrome who developed multiple renal lesions after interferon alfa therapy. Am J Kidney Dis 2004;44:567-573.","DOI":"10.1016\/S0272-6386(04)00828-5"},{"key":"ref53","unstructured":"Jadoul M, Piessevaux H, Ferrant A, Cosyns JP, van Ypersele de Strihou C. Renal thrombotic microangiopathy in patients with chronic myelogenous leukaemia treated with interferon-alpha 2b. Nephrol Dial Transplant 1995;10:111-113."},{"key":"ref54","doi-asserted-by":"crossref","unstructured":"Stratta P, Canavese C, Dogliani M, Thea A, Degani G, Mairone L, Vercellone A. Hemolytic-uremic syndrome during recombinant alpha-interferon treatment for hairy cell leukemia. Ren Fail 1993;15:559-561.","DOI":"10.3109\/08860229309054974"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198401053100107"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfh336"},{"key":"ref57","doi-asserted-by":"crossref","unstructured":"Fahal IH, Murry N, Chu P, Bell GM. Acute renal failure during interferon treatment. BMJ 1993;306:973.","DOI":"10.1136\/bmj.306.6883.973"},{"key":"ref58","doi-asserted-by":"crossref","unstructured":"Quesada JR, Talpaz M, Rios A, Kurzrock R, Gutterman JU. Clinical toxicity of interferons in cancer patients: a review. J Clin Oncol 1986;4:234-243.","DOI":"10.1200\/JCO.1986.4.2.234"},{"key":"ref59","doi-asserted-by":"crossref","unstructured":"Kurschel E, Metz-Kurschel U, Niederle N, Aulbert E. Investigations on the subclinical and clinical nephrotoxicity of interferon alpha-2B in patients with myeloproliferative syndromes. Ren Fail 1991;13:87-93.","DOI":"10.3109\/08860229109022152"},{"key":"ref60","doi-asserted-by":"crossref","unstructured":"Al-Wakeel J, Mitwalli A, Tarif N, Al-Mohaya S, Malik G, Khalil M. Role of interferon-alpha in the treatment of primary glomerulonephritis. Am J Kidney Dis 1999;33:1142-1146.","DOI":"10.1016\/S0272-6386(99)70153-8"},{"key":"ref61","doi-asserted-by":"crossref","unstructured":"Lederer E, Truong L. Unusual glomerular lesion in a patient receiving long-term interferon alpha. Am J Kidney Dis 1992;20:516-518.","DOI":"10.1016\/S0272-6386(12)70268-8"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1152\/ajpcell.00120.2007"},{"key":"ref63","unstructured":"Gresser I, Aguet M, Morel-Maroger L, Woodrow D, Puvion-Dutilleul F, Guillon JC, Maury C. Electrophoretically pure mouse interferon inhibits growth, induces liver and kidney lesions, and kills suckling mice. Am J Pathol 1981;102:396-402."},{"key":"ref64","unstructured":"Morel-Maroger L, Sloper JC, Vinter J, Woodrow D, Gresser I. An ultrastructural study of the development of nephritis in mice treated with interferon in the neonatal period. Lab Invest 1978;39:513-522."},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1159\/000355753"},{"key":"ref66","doi-asserted-by":"crossref","unstructured":"Schalm SW, Hansen BE, Chemello L, Bellobuono A, Brouwer JT, Weiland O, Cavalletto L, Schvarcz R, Ideo G, Alberti A. Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Meta-analysis of individual patient data from European centers. J Hepatol 1997;26:961-966.","DOI":"10.1016\/S0168-8278(97)80103-1"},{"key":"ref67","unstructured":"Kökény S, Papp J, Weber G, Vaszkó T, Carmona-Saez P, Oláh E. Ribavirin acts via multiple pathways in inhibition of leukemic cell proliferation. Anticancer Res 2009;29:1971-1980."},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0806104"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0807650"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0908014"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1012912"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60934-8"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1010494"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1009482"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12237"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12162"},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0000000000000081"},{"key":"ref78","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2015.1102882"},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402454"},{"key":"ref80","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1316366"},{"key":"ref81","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402355"},{"key":"ref82","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27890"},{"key":"ref83","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27726"},{"key":"ref84","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.06.004"},{"key":"ref85","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.02.044"},{"key":"ref86","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60494-3"},{"key":"ref87","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60538-9"},{"key":"ref88","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.10.013"},{"key":"ref89","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1306218"},{"key":"ref90","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2015.05.030"},{"key":"ref91","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2015.391"},{"key":"ref92","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1401561"},{"key":"ref93","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1315722"},{"key":"ref94","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402869"},{"key":"ref95","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402338"},{"key":"ref96","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.04.045"},{"key":"ref97","doi-asserted-by":"publisher","DOI":"10.5402\/2013\/159760"},{"key":"ref98","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2007.00868.x"},{"key":"ref99","doi-asserted-by":"crossref","unstructured":"Fabrizi F, Lunghi G, Andrulli S, Pagliari B, Mangano S, Faranna P, Pagano A, Locatelli F. Influence of hepatitis C virus (HCV) viraemia upon serum aminotransferase activity in chronic dialysis patients. Nephrol Dial Transplant 1997;12:1394-1398.","DOI":"10.1093\/ndt\/12.7.1394"},{"key":"ref100","doi-asserted-by":"publisher","DOI":"10.1159\/000013482"},{"key":"ref101","doi-asserted-by":"crossref","unstructured":"Alric L, Di-Martino V, Selves J, Cacoub P, Charlotte F, Reynaud D, Piette JC, Péron JM, Vinel JP, Durand D. Long-term impact of renal transplantation on liver fibrosis during hepatitis C virus infection. Gastroenterology 2002;123:1494-1499.","DOI":"10.1053\/gast.2002.36610"},{"key":"ref102","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2010060668"},{"key":"ref103","unstructured":"Alavian SM, Tabatabaei SV. Meta-analysis of factors associated with sustained viral response in patients on hemodialysis treated with standard or pegylated interferon for hepatitis C infection. Iran J Kidney Dis 2010;4:181-194."},{"key":"ref104","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2008.00990.x"},{"key":"ref105","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.01850309"},{"key":"ref106","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2007.11.003"},{"key":"ref107","doi-asserted-by":"crossref","unstructured":"Kamar N, Chatelut E, Manolis E, Lafont T, Izopet J, Rostaing L. Ribavirin pharmacokinetics in renal and liver transplant patients: evidence that it depends on renal function. Am J Kidney Dis 2004;43:140-146.","DOI":"10.1053\/j.ajkd.2003.09.019"},{"key":"ref108","doi-asserted-by":"crossref","unstructured":"Carriero D, Fabrizi F, Uriel AJ, Park J, Martin P, Dieterich DT. Treatment of dialysis patients with chronic hepatitis C using pegylated interferon and low-dose ribavirin. Int J Artif Organs 2008;31:295-302.","DOI":"10.1177\/039139880803100404"},{"key":"ref109","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2011.04741.x"},{"key":"ref110","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/159795"},{"key":"ref111","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2012.10.009"},{"key":"ref112","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12748"},{"key":"ref113","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2013.08.133"},{"key":"ref114","unstructured":"Bhamidimarri KR, Gutierrez JA, Grigorian A, Peyton L, Levy C, 0’Brien C, Martin P. Urgent Treatment With Sofosbuvir Based Regimen For Hepatitis C Genotype 1 Patients With Severe Renal Insufficiency (GFR <30ml\/min). Available from: http:\/\/liverlearning.aasld.org\/aasld\/2014\/thelivermeeting\/61050\/kalyan.bhamidimarri.urgent.treatment.with.sofosbuvir.based.regimen.for.html?f=p16m2t1370l1343<\/ext-link>."},{"key":"ref115","doi-asserted-by":"publisher","DOI":"10.1111\/liv.13025"},{"key":"ref116","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12148"},{"key":"ref117","doi-asserted-by":"crossref","unstructured":"Bruchfeld A, Wilczek H, Elinder CG. Hepatitis C infection, time in renal-replacement therapy, and outcome after kidney transplantation. Transplantation 2004;78:745-750.","DOI":"10.1097\/01.TP.0000131948.29742.24"},{"key":"ref118","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfm011"},{"key":"ref119","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e3181f92548"},{"key":"ref120","doi-asserted-by":"publisher","DOI":"10.1111\/liv.13022"},{"key":"ref121","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6135.2004.00676.x"},{"key":"ref122","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e318225dbae"},{"key":"ref123","doi-asserted-by":"publisher","DOI":"10.1097\/01.ASN.0000145896.16153.43"},{"key":"ref124","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2006.03151.x"},{"key":"ref125","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0090611"},{"key":"ref126","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.13620"},{"key":"ref127","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.13518"},{"key":"ref128","doi-asserted-by":"publisher","DOI":"10.1002\/lt.24126"},{"key":"ref129","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(15)30196-3"},{"key":"ref130","unstructured":"Huard G, Kim B, Patel A. Early Safety and Efficacy Profiles of Renal Transplant Recipients with Chronic Hepatitis C Treated with Sofosbuvir and Ribavirin. Available from: http:\/\/liverlearning.aasld.org\/aasld\/2014\/thelivermeeting\/60747\/genevieve.huard.early.safety.and.efficacy.profiles.of.renal.transplant.html?f=p14m2s169355<\/ext-link>."},{"key":"ref131","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27681"},{"key":"ref132","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v22.i4.1650"},{"key":"ref133","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(15)30129-X"},{"key":"ref134","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501315"},{"key":"ref135","doi-asserted-by":"crossref","unstructured":"Schwarz K, Murray KF, Rosenthal P, Bansal S, Lin CH, Ni L, Kanwar B, Fraser J, German P, Brainard DM. GS17: High Rates Of Svr12 In Adolescents Treated With The Combination Of Ledipasvir\/Sofosbuvir. Proceedings of The International Liver Congress™ 2016 - 51st annual meeting of the European Association for the Study of the Liver; April 13-17, 2016, Barcelona, Spain. J Hepatol 2016;64:S184-S185.","DOI":"10.1016\/S0168-8278(16)01697-4"}],"container-title":["World Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.wjgnet.com\/1948-5182\/full\/v8\/i32\/1343.htm","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,15]],"date-time":"2019-09-15T17:14:49Z","timestamp":1568567689000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.wjgnet.com\/1948-5182\/full\/v8\/i32\/1343.htm"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"references-count":135,"journal-issue":{"issue":"32","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.4254\/wjh.v8.i32.1343","relation":{},"ISSN":["1948-5182"],"issn-type":[{"value":"1948-5182","type":"print"}],"subject":[],"published":{"date-parts":[[2016]]}}}